This announcement is a separate document:
迈普医学：上海信公轶禾企业管理咨询有限公司关于广州迈普再生医学科技股份有限公司2024年限制性股票激励计划（草案）之独立财务顾问报告
Medprin Regenerative Medical Technologies: Independent financial advisor report on 2024 Restricted Stock Incentive Plan (Draft) of Guangzhou Maipu Regenerative Medical Technology Co., Ltd. by Shanghai Xingong Yihe Enterprise Management Consulting Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.